Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054298
| Line item | Three Months Ended June 30, 2026 | 2025 | Six Months Ended June 30, 2026 | 2025 |
|---|---|---|---|---|
| Research and development (1) | 30,433 | 31,065 | 60,538 | 79,735 |
| General and administrative (1) | 11,108 | 15,986 | 23,831 | 35,639 |
| Stock-based compensation (2) | 8,037 | 18,770 | 24,745 | 36,483 |
| Depreciation and amortization | 12,315 | 15,249 | 25,114 | 30,071 |
| Restructuring charges (3) | — | 3,566 | — | 8,032 |
| Carrying cost of excess space (net of sublease income) (4) | 14,233 | 12,413 | 30,074 | 24,088 |
| Merger and acquisition related expense (income) (5) | 1,106 | (3,617) | 1,106 | (4,535) |
| Other (income) expense, net (6) | (1,355) | (4,686) | 3,410 | (2,436) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ginkgo Bioworks's D&A?
- Ginkgo Bioworks (DNA) reported D&A of $12.32M in Q2 2026.
- How has Ginkgo Bioworks's D&A changed year-over-year?
- Ginkgo Bioworks's D&A decreased by 19.2% year-over-year, from $15.25M to $12.32M.
- What is the long-term trend for Ginkgo Bioworks's D&A?
- Over 4 years (2021 to 2025), Ginkgo Bioworks's D&A has grown at a 19.3% compound annual growth rate (CAGR), from $29.08M to $58.99M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Ginkgo Bioworks's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude